"Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study" by Laura C Coates

Article

Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study

Arthritis Care and Research (2018)

Laura C Coates, University of Oxford
Philip J Mease, University of Washington
Laure Gossec, University of Paris
Bruce Kirkham, Guy's and St Thomas' NHS Foundation Trust
Bintu Sherif, Research Triangle Park
Corine Gaillez, Novartis
Shephard Mpofu, Novartis
Steffen M Jugl, Novartis
Chetan Karyekar, Novartis
Kunal K Gandhi, Novartis

Link

Disciplines

Physical Therapy,
Medicine and Health Sciences and
Endocrinology, Diabetes, and Metabolism

Publication Date

February 6, 2018

DOI

10.1002/acr.23537

Citation Information

Laura C Coates, Philip J Mease, Laure Gossec, Bruce Kirkham, et al.. "Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study" Arthritis Care and Research (2018)
Available at: http://works.bepress.com/philip-mease/15/